Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Imatinib - Tenax Therapeutics

Next Previous
X
Search
Drug Profile

Imatinib - Tenax Therapeutics

Alternative Names: TNX 201; TNX-201 - Tenax Therapeutics

Latest Information Update: 28 Feb 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PHPrecisionMed
  • Class Amines; Anti-inflammatories; Antineoplastics; Antivirals; Benzamides; Eye disorder therapies; Piperazines; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Bcr-Abl tyrosine kinase inhibitors; Platelet-derived growth factor receptor antagonists; Proto-oncogene protein c-kit inhibitors; Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension
  • New Molecular Entity No

Highest Development Phases

  • No development reported Pulmonary arterial hypertension

Most Recent Events

  • 28 Feb 2024 No recent reports of development identified for clinical-Phase-Unknown development in Pulmonary-arterial-hypertension(In volunteers) in USA (PO, Controlled release)
  • 03 Feb 2023 Tenax Therapeutics anticipates regulatory approval for imatinib for Pulmonary arterial hypertension
  • 15 Sep 2022 Tenax Therapeutics plans the pivotal phase III IMPROVE trial for Pulmonary arterial hypertension in USA (PO), in 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top